Neuland Laboratories (NEULANDLAB) Share Price Falls 3.55%: What the Stock News Shows Today

Published:   31 August 2026 at 3:33:21 PM IST

Neuland Laboratories Share Price fell today to Rs 22,400, down 3.55% from the previous close, with the company’s market capitalisation at Rs 29,797.99 crore. The move places Neuland Laboratories in focus for investors following Neuland Laboratories Share Price Today and the latest Neuland Laboratories Stock News, even though the supplied data confirms the price event without establishing a company-specific catalyst. Neuland Laboratories Share Price has moved sharply enough to draw attention because the decline came after a session that opened and reached Rs 23,225 before easing to the day’s low of Rs 22,400. On Univest, the same data points help frame today’s share price fall against the stock’s valuation, healthcare sector position and peer comparison.

Neuland Laboratories (NEULANDLAB) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 22,400
Previous Close	Rs 23,225.45
Today's Move	-Rs 825.45 (-3.55%)
Open	Rs 23,225
High	Rs 23,225
Low	Rs 22,400
Turnover	Rs 5.21 crore
Market Capitalisation	Rs 29,797.99 crore
Market Cap Category	Large Cap

Neuland Laboratories Share Price Today closed the session at Rs 22,400, compared with the previous close of Rs 23,225.45. That leaves a day change of Rs -825.45, or -3.55%. The stock opened at Rs 23,225 and also hit the same level as the day high, before touching the day low of Rs 22,400. This means the session moved steadily lower after the open, and the final price matched the day’s low.

For context, Neuland Laboratories Share Price News also needs to be read with the company’s size. Neuland Laboratories is categorised as a Large Cap stock, and its market capitalisation stands at Rs 29,797.99 crore. The turnover for the day is Rs 5.21 crore. The supplied data confirms the price event, but it does not establish a company-specific reason behind the decline.

From a market-news perspective, Neuland Laboratories Share Price Fall is best described as a same-day decline that followed a flat opening near the prior close and ended at the session low. Investors tracking Neuland Laboratories Stock Falling Today will therefore focus on whether the next session keeps the price near this level or recovers back toward the previous close. Neuland Laboratories Share Price Update, in other words, is about the direction of the current session rather than any uncovered trigger.

Neuland Laboratories (NEULANDLAB) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 29,797.99 crore
P/E Ratio	59.86x
P/B Ratio	14.74x
ROE	21.43%
ROCE	27.5%
EPS	Rs 387.98
Book Value Per Share	Rs 1,575.41
Dividend Yield	0.15%

Neuland Laboratories Fundamental Analysis shows a premium valuation profile in the context of the broader healthcare universe. The stock trades at a P/E ratio of 59.86 and a P/B ratio of 14.74. Its ROE is 21.43%, while ROCE stands at 27.5%, both of which indicate strong return metrics on the supplied figures. EPS is Rs 387.98 and book value per share is Rs 1,575.41, which gives a clear accounting and earnings base for Neuland Laboratories Share Price Today.

Dividend yield is 0.15%, which is a factual income metric and not a forecast. On market capitalisation, Neuland Laboratories Market Cap of Rs 29,797.99 crore places it far above the median market cap of Rs 670.73 crore in the supplied industry benchmark. Enterprise value is not supplied, so the analysis stays with the exact available data. Neuland Laboratories Stock Analysis therefore reflects a company with strong profitability ratios and a valuation that is higher than many industry names in the benchmark set. For readers following Neuland Laboratories Latest News, the key point is that today’s share price fall occurred against a background of substantial earnings and return metrics, not against weak fundamental disclosure in the supplied dataset.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	59.86x
Benchmark Median P/E	31.21x
Benchmark Average P/E	48.1x
Benchmark P/E Range	3.7x to 672.45x
Company P/B Ratio	14.74x
Benchmark Median P/B	2.88x
Benchmark Average P/B	4.19x
Company ROE	21.43%
Benchmark Median ROE	11.78%
Benchmark Average ROE	10.68%
Company ROCE	27.5%
Benchmark Median ROCE	13.6%
Benchmark Average ROCE	13.27%
Company Market Capitalisation	Rs 29,797.99 crore
Benchmark Median Market Cap	Rs 670.73 crore
Benchmark Average Market Cap	Rs 14,040.53 crore

The sector snapshot places Neuland Laboratories in Healthcare, within Pharmaceuticals & Drugs, against a same-industry benchmark of 203 companies. That is an important reference point for Neuland Laboratories Share Price because valuation and return ratios can be read against a broad peer universe. The company’s P/E of 59.86 is above the benchmark median of 31.21 and above the benchmark average of 48.1. Its P/B of 14.74 is also above the benchmark median of 2.88 and above the benchmark average of 4.19.

On profitability, Neuland Laboratories shows ROE of 21.43% versus the benchmark median of 11.78% and average of 10.68%. ROCE of 27.5% is also above the benchmark median of 13.6% and average of 13.27%. In market-cap terms, the company’s Rs 29,797.99 crore value is far above the benchmark median of Rs 670.73 crore and above the benchmark average of Rs 14,040.53 crore. This means Neuland Laboratories Share Price is being viewed in a large-company context inside a wide pharmaceuticals peer set, where the company stands well above the benchmark midpoint on size and returns.

For investors searching Neuland Laboratories Stock News or Neuland Laboratories News Today, the sector takeaway is simple: the healthcare and pharmaceuticals backdrop is information-rich, and the company’s valuation sits above the benchmark middle while profitability ratios also sit above the benchmark middle. The supplied data supports comparison, not a conclusion about cause.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,60,696.31	38.09	5.33	14.85	19.11
Divi's Laboratories	DIVISLAB	2,46,062.83	84.12	13.93	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,91,515.22	87.81	21.34	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,18,403.7	26.24	4.39	19.69	21.39
Cipla	CIPLA	1,14,554.33	33.99	3.26	11.83	16

Against peers, Neuland Laboratories Share Price sits in a group that includes Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla The company’s market capitalisation of Rs 29,797.99 crore is below Sun Pharma, Divi’s, Torrent, Zydus and Cipla in the supplied peer set, but it is still well above the benchmark median for the industry.

On valuation, Neuland Laboratories’ P/E of 59.86 is higher than Sun Pharma, Zydus and Cipla, but lower than Divi’s, Torrent and Laurus Labs in the wider peer data. Its P/B of 14.74 is also above Sun Pharma, Zydus and Cipla, while remaining below Torrent and Laurus Labs. ROE at 21.43% is stronger than Sun Pharma, Divi’s, Zydus and Cipla, though below Torrent and Lupin in the broader peer field. ROCE of 27.5% is above Sun Pharma, Divi’s, Zydus and Cipla, and close to the stronger return profiles in the group. For readers tracking Neuland Laboratories Share Price Today, these comparisons show a stock with richer valuation ratios but also stronger return metrics than several of the listed healthcare peers.

Why Investors Are Watching Neuland Laboratories

• Neuland Laboratories Share Price fell 3.55% today to Rs 22,400 from the previous close of Rs 23,225.45.
• The day open, day high and session start were all Rs 23,225, while the day low and last price were Rs 22,400.
• Market capitalisation stands at Rs 29,797.99 crore, and the company is classified as a Large Cap stock.
• P/E is 59.86, P/B is 14.74, ROE is 21.43% and ROCE is 27.5% in the supplied fundamentals.
• The healthcare industry benchmark covers 203 companies, and Neuland Laboratories’ valuation and returns sit above the benchmark median on several measures.

About Neuland Laboratories

Neuland Laboratories operates in Healthcare and the Pharmaceuticals & Drugs industry. The supplied data identifies the company through its sector and industry classification, and the current analysis therefore stays focused on those verified identifiers. Neuland Laboratories Share Price Today is being tracked in the market in the context of this sector positioning and the company’s exact financial ratios.

For anyone following Neuland Laboratories Stock Analysis, the useful starting point is the combination of market cap, profitability and valuation metrics already supplied. Univest uses these verified data points to keep the discussion factual and aligned with the company’s listed identity.

Track Neuland Laboratories Share Price on Univest

Use Neuland Laboratories (NEULANDLAB) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

You can track Neuland Laboratories Share Price Live on Univest with the latest market cap, P/E ratio, P/B ratio, ROE, ROCE, EPS, book value, dividend yield, sector context and peer comparison. Univest also helps users follow Neuland Laboratories Share Price Update and Neuland Laboratories Share News in one place.

Frequently Asked Questions

Why is Neuland Laboratories Share Price falling today?

Ans.  Neuland Laboratories Share Price fell 3.55% to Rs 22,400 today. The supplied data confirms the move and the session range, but it does not establish a company-specific catalyst for the decline.

What is Neuland Laboratories Share Price Today?

Ans.  Neuland Laboratories Share Price Today is Rs 22,400. It is down from the previous close of Rs 23,225.45, after opening and touching Rs 23,225 before ending at the day’s low.

What is Neuland Laboratories market capitalisation?

Ans.  Neuland Laboratories market capitalisation is Rs 29,797.99 crore. The stock is classified as a Large Cap company in the supplied data, which helps frame its position in the healthcare universe.

What do Neuland Laboratories valuation ratios show?

Ans.  Neuland Laboratories trades at a P/E of 59.86 and a P/B of 14.74. In the supplied industry benchmark, both ratios sit above the benchmark median, which provides valuation context. The company trades at a P/E ratio of 59.86x.

How strong are Neuland Laboratories profitability ratios?

Ans.  Neuland Laboratories reports ROE of 21.43% and ROCE of 27.5%. Both figures are above the supplied industry benchmark median, while EPS is Rs 387.98 and book value is Rs 1,575.41.

How does Neuland Laboratories compare with pharma peers?

Ans.  Neuland Laboratories has a smaller market cap than Sun Pharma, Divi’s, Torrent, Zydus and Cipla in the supplied peer set, but its ROE and ROCE are stronger than several of those peers.

What is the dividend yield of Neuland Laboratories?

Ans.  Neuland Laboratories has a dividend yield of 0.15%. This is a factual income metric in the current dataset and should be read alongside the company’s earnings, book value and valuation ratios.